Moderna, Inc. Operating Income Loss

• Moderna, Inc. showed an increase of +22.1% in Operating Income Loss from 2024 to 2025.
• This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Moderna, Inc.'s Operating Income Loss has declined by 1,273.7%.
• Historical annual values: Fiscal year 2025: -$3.07 billion | Fiscal year 2024: -$3.95 billion | Fiscal year 2023: -$4.24 billion | Fiscal year 2022: $9.42 billion | Fiscal year 2021: $13.30 billion | Fiscal year 2020: -$763.00 million | Fiscal year 2019: -$546.00 million | Fiscal year 2018: -$413.27 million | Fiscal year 2017: -$269.36 million | Fiscal year 2016: -$223.77 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026